Project Grant R01HL179093
Award Date
5/21/25
Completion Date
3/31/30
Dollars Obligated
$704K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
The federal Project Grant award, totaling $200,000.00 and running from September 17, 2024 to September 16, 2025, was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research focused on studying the effect of NRF2 activation on the phenotype of vascular smooth muscle cells (VSMCs) and assessing a new local therapeutic approach that activates NRF2...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $407,975.00 to Arizona State University to develop a lesion-targeted nanotherapeutic that utilizes CARMN transcripts for the treatment of vascular smooth muscle cell dysfunction and neointimal hyperplasia. The research aims to optimize the nanoparticle delivery system, investigate the pharmacokinetics and toxicity, and evaluate...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $499,890 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Pavaj Vascular Corporation located in Rochester, MN. The funding will support the development and evaluation of a novel nanoparticle-based therapy to prevent venous stenosis and improve arteriovenous fistula function in patients with end-stage kidney disease requiring hemodialysis. Key project goals include...
This federal Project Grant award, provided by the National Heart Lung and Blood Institute (NHLBI) under CFDA Program 93.837 Cardiovascular Diseases Research, will fund research to elucidate the role of RNA-mediated epigenetic and epitranscriptional mechanisms in diabetic endotheliopathy and vasculopathy. The total funding amount is $543,268, with a project period from July 1, 2024 to June 30, 2031. The key products and services to be delivered under this grant include: Identifying the roles...
This $691,326 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research aims to develop a "4D Right-Heart Virtual Catheter (VCATH)" technology. This non-invasive diagnostic tool leverages 4D flow MRI scans to provide a comprehensive hemodynamic analysis of all right heart chambers in under 2 minutes. The project involves a multi-center study across 3 sites (Northwestern, Mayo Clinic, UT Southwestern) to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research at the University of Rochester to determine how the protein kinase D3 (PKD3) regulates endothelial-mesenchymal transition (EndMT) and heart valve development, function, and disease. The $581,493 award, effective August 1, 2024 through July 31, 2025, aims to provide a better understanding of the molecular pathways...
This federal Project Grant award of $686,458, awarded on July 10, 2024 by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project focused on developing a quantitative, predictive model of vascular remodeling in health and disease. The key objective is to acquire quantitative data on the interactions within vascular remodeling regulatory networks and develop a computational model that can accurately...
The National Institute of General Medical Sciences (NIGMS) awarded a $1,248,750 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Mayo Clinic Arizona to develop durable cell-based therapies for treating chronic diseases. The goal is to engineer cells that secrete therapeutic proteins and can be grafted into the body as biological "drug factories" to provide long-term cures for conditions like hemophilia, diabetes, and liver disorders. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $1,309,340 award will support research at the University of Arizona to investigate the role of coronary microvascular dysfunction as a mechanism contributing to heart failure with preserved ejection fraction (HFpEF). The researchers will use a mouse model of HFpEF induced by a high-fat,...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $591,844 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Allvivo Vascular, Inc. The goal of this 1-year project is to develop a catheter end cap with an antimicrobial luminal insert to reduce the risk of bloodstream infections in hemodialysis patients. The cap features a novel antimicrobial peptide called ASP-2 that is designed to be released into...